Efficacy And Safety Of Qva149 Versus Glycopyrronium And Tiotropium In A Subgroup Of Patients With Severe COPD: The Spark Study

被引：0
|
作者：
Wedzicha, J. [1 ]
D'Urzo, A. D. [2 ]
Decramer, M. [3 ]
Ficker, J. H. [4 ]
Sandstrom, T. [5 ]
Taylor, A. Fowler [6 ]
D'Andrea, P. [6 ]
Mezzi, K. [7 ]
Chen, H. [6 ]
Banerji, D. [6 ]
Fogel, R. [6 ]
机构：
[1] UCL, London, England
[2] Univ Toronto, Toronto, ON, Canada
[3] Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium
[4] Klinikum Nuernberg, Nurnberg, Germany
[5] Umea Univ, Umea, Sweden
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5986
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Once-Daily Qva149 Improves Health-Related Quality Of Life In Patients With Severe To Very Severe COPD: The Spark Study
    Decramer, M.
    Wedzicha, J. A.
    Ficker, J.
    Taylor, A. Fowler
    D'Andrea, P.
    Arrasate, C.
    Berhane, I.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [32] Qva149 Significantly Lowers The Rate And Risk Of Moderate Or Severe COPD Exacerbation Versus Salmeterol/fluticasone In Patients With Moderate To Severe COPD: The Lantern Study
    Zhong, N.
    Wang, C.
    Zhou, X.
    Zhang, N.
    Patalano, F.
    Humphries, M.
    Wang, L.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [33] Efficacy and Safety of QVA149, a Fixed-Dose Combination of Indacaterol and Glycopyrrolate in Symptomatic Patients With Moderate to Severe COPD: Effect of Gender
    Yadao, Anthony
    Fucile, Sebastian
    Shen, Steven
    Ayers, Tim
    Banerji, Donald
    Fogel, Robert
    CHEST, 2016, 150 (04) : 822A - 822A
  • [34] Once-Daily Qva149 Provides Clinically Meaningful Improvements In Lung Function And Clinical Outcomes Versus Placebo, Indacaterol, Glycopyrronium, Tiotropium And Salmeterol/fluticasone In Patients With COPD
    Vogelmeier, C.
    Dahl, R.
    D'Urzo, T.
    Chen, H.
    Green, Y.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [35] BENEFITS OF DUAL BRONCHODILATION WITH QVA149 ONCE DAILY VERSUS PLACEBO, INDACATEROL, NVA237 AND TIOTROPIUM IN PATIENTS WITH COPD: THE SHINE STUDY
    Frith, P.
    Thompson, P.
    Wark, P.
    Lindstrom, S.
    Bateman, E.
    RESPIROLOGY, 2013, 18 : 20 - 20
  • [36] Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study
    Bateman, Eric
    Ferguson, Gary T.
    Barnes, Neil
    Gallagher, Nicola
    Green, Yulia
    Horton, Rachael
    Henley, Michelle
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [37] Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study
    Dahl, Ronald
    Jadayel, Dalal
    Alagappan, Vijay
    Chen, Hungta
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [38] Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-very severe COPD: A pooled analysis
    Dahl, Ronald
    Buhl, Roland
    Mezzi, Karen
    Schubert-Tennigkeit, Agnes
    Chen, Hungta
    Banerji, Donald
    Fogel, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [39] Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients
    Van de Maele, Boudewijn
    Fabbri, Leonardo M.
    Martin, Carmen
    Horton, Rachael
    Dolker, Michael
    Overend, Tim
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2010, 7 (06) : 418 - 427
  • [40] Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-very severe COPD: A pooled analysis
    Dahl, Ronald
    Buhl, Roland
    Mezzi, Karen
    Schubert-Tennigkeit, Agnes
    Chen, Hungta
    Banerji, Donald
    Fogel, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
12345